当前位置: 首页 >> 检索结果
7025. Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis.
Diagnosis of transient ischaemic attacks (TIAs) can be difficult. There is consensus on classic symptoms (eg, motor weakness, dysphasia, hemianopia, monocular visual loss) but no consensus on several monosymptomatic events with sudden-onset, non-progressive, focal negative symptoms (eg, isolated diplopia, dysarthria, vertigo, ataxia, sensory loss, and bilateral visual disturbance), with much variation in investigation and treatment.
7026. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
作者: Anthony R Mato.;Nirav N Shah.;Wojciech Jurczak.;Chan Y Cheah.;John M Pagel.;Jennifer A Woyach.;Bita Fakhri.;Toby A Eyre.;Nicole Lamanna.;Manish R Patel.;Alvaro Alencar.;Ewa Lech-Maranda.;William G Wierda.;Catherine C Coombs.;James N Gerson.;Paolo Ghia.;Steven Le Gouill.;David John Lewis.;Suchitra Sundaram.;Jonathon B Cohen.;Ian W Flinn.;Constantine S Tam.;Minal A Barve.;Bryone Kuss.;Justin Taylor.;Omar Abdel-Wahab.;Stephen J Schuster.;M Lia Palomba.;Katharine L Lewis.;Lindsey E Roeker.;Matthew S Davids.;Xuan Ni Tan.;Timothy S Fenske.;Johan Wallin.;Donald E Tsai.;Nora C Ku.;Edward Zhu.;Jessica Chen.;Ming Yin.;Binoj Nair.;Kevin Ebata.;Narasimha Marella.;Jennifer R Brown.;Michael Wang.
来源: Lancet. 2021年397卷10277期892-901页
Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of pirtobrutinib (working name; formerly known as LOXO-305), a highly selective, reversible BTK inhibitor, in these patients.
|